Announcements Trials
Browse Landscape

Status

Approved for marketing 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 211Observational 17Expanded_access 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 2Urogenital Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Genital Neoplasms, Male 1Genital Diseases, Male 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × Abiraterone Acetate × Clear all
NCT05401214 2025-06-13

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Janssen Research & Development, LLC

Approved for marketing
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT01834209 2018-11-07

A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Janssen Research & Development, LLC

No longer available
Genitourinary

Prostatic Neoplasms

NCT01217697 2017-03-24

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Approved for marketing
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡